| Literature DB >> 27199747 |
Himadri Kalita1, Dulal C Boruah2, Meetali Deori1, Ankita Hazarika1, Rahul Sarma1, Sima Kumari1, Raghuram Kandimalla3, Jibon Kotoky3, Rajlakshmi Devi1.
Abstract
Folklore studies have revealed that Musa balbisiana Colla (MB; Family: Musaceae) has high medicinal properties. The purpose of the present study is to evaluate antihyperglycemic, and antioxidant activity of MB extracts in streptozotocin (STZ) induced diabetic rats. In vitro antioxidant and antidiabetic activity of MB extracts, i.e., root extract (RE), shoot extract and inflorescence extract were determined by using various methods viz 1,-1-diphenyl-2-picrylhydrazyl (DPPH) and a method to assess their possible effect on glucose diffusion across gastrointestinal tract and identify bioactive compound of potent extract. In vivo antilipidemic and antidiabetic activity was evaluated by administrating oral dose of RE for 15 days on STZ- induced diabetic rat. RE showed highest antioxidant activity by scavenging DPPH radical (IC50 32.96 μg/ml) and inhibit 30% glucose movement in vitro. The methanol extract of root showed the presence of calyx [4] arene category of the compound. Furthermore, RE treated rat revealed a reduction in fasting blood glucose (62.5%), serum total cholesterol (36.2%), triglyceride (54.5%), and low-density lipoprotein (50.94%) after 15 days as compared to STZ treated animal. There was an initiation of regenerative structures of the affected organs after 15 days of RE treatment. Histopathological observations clearly differentiate the structural changes in pancreas, liver, and kidney of STZ and RE treated group. The presence of calyx [4] arene class of compound may be responsible for its antioxidant and antidiabetic properties by absorbing glucose in vivo.Entities:
Keywords: antioxidant; crude fiber; free radical; hyperglycemia; hyperlipidemia
Year: 2016 PMID: 27199747 PMCID: PMC4852310 DOI: 10.3389/fphar.2016.00102
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Changes in levels of serum lipid profile (TC, TG, HDL-c, LDL-c, and VLDL-c) and oxidative stress markers (SOD, GSH, Catalase, TBARS, and NO) in serum and liver in groups A, B, C, and D.
| Parameters | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| TC (mg/dl) | 70.34 ± 1.9 | 186.23 ± 34.13+ | 119.36 ± 6.01** | 111.1 ± 4.1 |
| TG (mg/dl) | 120 ± 0.86 | 149.40 ± 8.28 | 127.54 ± 7.63* | 129.29 ± 7.61 |
| HDL-c (mg/dl) | 37.66 ± 0.89 | 21.90 ± 2.58 | 30.33 ± 5.55 | 34.33 ± 10.12 |
| LDL-c (mg/dl) | 56.76 ± 1.49 | 194.21 ± 5.57++ | 114.53 ± 3.40* | 102.62 ± 7.5 |
| VLDL-c (mg/dl) | 24 ± 0.17 | 29.88 ± 5.6 | 25.50 ± 3.45 | 25.85 ± 3.45 |
| Serun SOD (% SOD) | 33.52 ± 1.34 | 22.19 ± 3.00+ | 48.79 ± 8.9** | 48.66 ± 0.57 |
| Serum GSH (ug/ml) | 1300.67 ± 49 | 1134.66 ± 54.45 | 2552 ± 579.75 | 2873.33 ± 148.4 |
| Serum catalase (unit mg protein) | 152.71 ± 2.4 | 44 ± 6.55++ | 112.06 ± 17.52** | 115.53 ± 12.78 |
| Serum TBARS (nmole/ml) | 28.7 ± 2.23 | 37.7 ± 4.66 | 23.24 ± 6.07 | 20.56 ± 4.56 |
| Serum NO (uM/ml) | 23.19 ± 4.11 | 30.92 ± 5.89 | 25.03 ± 2.33 | 24.29 ± 3.56 |
| Liver SOD (% SOD) | 68 ± 0.89 | 32.29 ± 10.39+ | 57.71 ± 3.03 | 61.65 ± 6.24 |
| Liver GSH (ug/gm) | 1361.33 ± 120.3 | 896 ± 148.1++ | 1364.66 ± 30.74 | 1416.66 ± 104 |
| Liver catalase (unit mg protein) | 26.12 ± 2.42 | 17.50 ± 2.42+ | 39.02 ± 1 | 42.03 ± 2.61 |
| Liver TBARS (nmole/mg tissue) | 31.23 ± 2.4 | 50.3 ± 1.48++ | 22.85 ± 0.18 | 24.91 ± 4.96 |
| Liver NO (uM/mg) | 23.92 ± 5.67 | 40.91 ± 3.44 | 28.61 ± 6.11 | 27.60 ± 5.55 |